An interview with Bayer's Bernardo Kanahuati, senior vice president, global head cardiorenal and product team lead, Kerendia, and Katja Rohwedder, senior medical affairs physician, global medical ...

In its See Your Risks campaign, Bayer takes aim at denial among millennials and Gen Xers when it comes to heart disease. To ...

Bayer is worried about your heart health. | Older millennials, take note: Bayer is worried about your heart health. The drugmaker set out its concerns in an ad for aspirin, showing how people are ...

head of Bayer’s pharma division, said at the J.P. Morgan Healthcare Conference in January. The move comes after a Filspari phase 3 trial in that indication failed on its primary endpoint of eGFR ...

On January 21, a Northern District of California Court denied Plaintiff Tevra Brands LLC’s (“Tevra’s”) Motion for a New Trial, after a Jury found ...

J.P. Morgan analyst Richard Vosser maintained a Hold rating on Bayer (0P6S – Research Report) today and set a price target of €25.00. The ...

Bayer seeks European approval of extended 6-month treatment interval for Eylea 8 mg to treat nAMD & diabetic macular edema: Berlin Tuesday, February 11, 2025, 10:00 Hrs [IST] Baye ...

Bayer is committed to advancing treatment in prostate cancer care, showcasing new analyses from its comprehensive clinical trial program for NUBEQA ® (darolutamide), which includes the ARANOTE, ...

Berlin: Bayer has announced the submission of a marketing authorization application to the European Medicines Agency (EMA), ...